S&P 500 Healthcare Sector SEC Filings — March 27, 2026

27-03-2026

Alamar Biosciences, Inc. filed an S-1 registration statement on March 27, 2026, for an initial public offering on Nasdaq under the symbol 'ALMR', with financials showing strong revenue growth from $25.1M in 2024 to $74.2M in 2025 (195% YoY), driven by product revenue surging 249% to $58.4M and gross profit expanding 385% to $41.7M. However, operating expenses increased 26% to $73.0M, largely from SG&A doubling to $35.6M while R&D dipped slightly by 4% to $37.5M, resulting in a reduced net loss of $29.8M from $47.1M YoY but ongoing unprofitability. The company held $30.0M in cash as of December 31, 2025, with $56.5M convertible notes issued in January 2026.

• ·Stock-based compensation expense increased to $2.9M in 2025 from $0.9M in 2024.
• ·Total assets $140.0M and stockholders' deficit $(158.9M) as of Dec 31, 2025.
• ·Net loss per share, basic, improved to $(1.07) in 2025 from $(1.82) in 2024.
• ·Weighted-average exercise price for 2018 Plan options: $1.32 per share as of Dec 31, 2025.
• ·Weighted-average exercise price for warrants: $1.47 per share as of Dec 31, 2025.
• ·Series C Warrant exercise price: $2.9775 per share.
• ·Phantom Plan weighted-average exercise price: $1.79 per share.

27-03-2026

COMMUNITY FINANCIAL SYSTEM, INC. (CBU) filed a DEFA14A Definitive Additional Proxy Materials on March 27, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is by the registrant with no fee required and no substantive proposals, financial data, or changes detailed in the provided header content. This appears to be supplemental material to prior proxy statements.

27-03-2026

Kodiak Sciences Inc. announced positive topline results from GLOW2, its second Phase 3 study in diabetic retinopathy, demonstrating superiority of Zenkuda™ (tarcocimab tedromer) over sham. The press release detailing these results is attached as Exhibit 99.1 and incorporated by reference. The filing was signed by CEO Victor Perlroth, M.D. on March 26, 2026.

• ·Filing date: March 27, 2026; Date of earliest event: March 26, 2026
• ·Registrant details: Delaware incorporation, CIK 0001468748, Nasdaq: KOD
• ·Principal offices: 1250 Page Mill Road, Palo Alto, CA 94304

27-03-2026

News Corporation disclosed information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, which authorizes up to $1 billion in aggregate repurchases of Class A and Class B common stock. The disclosures, attached as Exhibits 99.1 and 99.2, are made daily as required by ASX rules if transactions occur and include forward-looking statements about repurchase intentions subject to market conditions and risks. No specific transaction amounts or performance metrics were detailed in the filing.

• ·Event date: March 26, 2026
• ·Filing date: March 27, 2026
• ·Securities: Class A Common Stock (NWSA), Class B Common Stock (NWS) on Nasdaq Global Select Market

27-03-2026

Werewolf Therapeutics reported Q4 and FY2025 financial results showing significant YoY reductions in R&D expenses (Q4: $6.9M vs $15.7M, -56%; FY: $44.8M vs $56.4M, -21%) and G&A expenses (Q4: $2.5M vs $4.6M, -46%; FY: $15.8M vs $19.0M, -17%), leading to narrower net losses (Q4: $8.4M vs $20.4M; FY: $60.8M vs $70.5M). However, cash and equivalents declined to $57.1M from $65.7M in Q3 2025 and $111.0M at end-2024, with runway only into Q4 2026, amid zero revenue compared to $1.9M in FY2024. The company is exploring strategic alternatives including potential sale or merger, with Piper Sandler engaged as advisor.

• ·Cash runway sufficient into Q4 2026.
• ·Working capital $22.4M as of Dec 31, 2025 (vs $97.9M end-2024).
• ·Total assets $69.4M as of Dec 31, 2025 (vs $126.9M end-2024).
• ·No defined timeline for strategic review process.

27-03-2026

Editas Medicine, Inc. issued a press release announcing that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s previous decision favoring the Broad Institute in the CRISPR/Cas9 patent interference for editing in human cells. The decision follows a remand from the U.S. Court of Appeals for the Federal Circuit’s May 2025 ruling, which affirmed-in-part and vacated-in-part the prior PTAB decision. The interference involves the Broad Institute, Massachusetts Institute of Technology, and Harvard University against the University of California, University of Vienna, and Emmanuelle Charpentier (collectively 'CVC'), with CVC retaining appeal rights to the CAFC.

• ·Event occurred on March 26, 2026; press release issued March 27, 2026
• ·CAFC decision in May 2025 affirmed-in-part and vacated-in-part prior PTAB ruling

27-03-2026

Arrow Financial Corp (AROW) filed a 10-K/A amendment on March 27, 2026, confirming its status as an accelerated filer. The filing includes attestation to management's assessment of internal control over financial reporting under Section 404(b) of Sarbanes-Oxley by its registered public accounting firm. No corrections to previously issued financial statements or restatements requiring recovery analysis of executive compensation were indicated.

• ·Registrant is not a large accelerated filer, non-accelerated filer, smaller reporting company, emerging growth company, or shell company.
• ·No election for extended transition period for new financial accounting standards.

27-03-2026

Satellos Bioscience Inc. filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference the Annual Information Form (Exhibit 99.1), audited consolidated financial statements for 2025 and 2024 (Exhibit 99.2), and MD&A (Exhibit 99.3). As of December 31, 2025, the company reported 15,458,903 common shares outstanding, traded on Nasdaq under symbol MSLE. No material changes in internal controls or disclosures of errors in prior financials were noted; the company qualifies as an emerging growth company.

• ·Auditor: PricewaterhouseCoopers LLP (Toronto, Canada).
• ·Audit Committee members determined independent and financially literate; Adam Mostafa designated audit committee financial expert.
• ·No notices sent under Rule 104 of Regulation BTR during 2025.
• ·Company is a foreign private issuer following certain home country practices in lieu of Nasdaq rules.

27-03-2026

National CineMedia, Inc. amended Section 3.02 of its Amended and Restated Bylaws to increase the number of directors from seven (7) to eight (8), effective immediately prior to the 2026 annual meeting of stockholders on May 7, 2026. The amendment was adopted by resolution of the Board of Directors effective March 26, 2026, pursuant to Section 7.08 of the Bylaws and Article XI of the Certificate of Incorporation. No other changes were made to the Bylaws.

• ·Annual meeting scheduled at 9:30 a.m. Eastern Time on May 7, 2026.
• ·Directors need not be residents of Delaware or stockholders; no decrease in board size shortens incumbent terms.

27-03-2026

Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for a public offering of 6,976,744 shares of Class A common stock at $2.15 per share, with net proceeds estimated at $13.5 million (or $16.0 million if the 30-day option for 1,046,511 additional shares is exercised in full). The offering is expected to close on or about March 27, 2026, subject to customary closing conditions, including risks that could prevent completion. The agreement includes a 7.0% underwriting discount and up to $150,000 expense reimbursement, with a 60-day lock-up for the company, directors, and executives.

• ·Offering made pursuant to shelf registration on Form S-3 (File No. 333-273062), effective October 27, 2023.
• ·Prospectus supplement filed with SEC on March 26, 2026.
• ·Event date: March 25, 2026; expected closing on or about March 27, 2026.

27-03-2026

Ally Auto Receivables Trust 2022-3 filed its 10-K annual report on March 27, 2026, covering the year ended December 31, 2025. Financial statements and schedules are not applicable; the filing primarily lists exhibits including formation agreements from December 14, 2022, and compliance reports from Ally Bank and U.S. Bank Trust Company, National Association. No operational or financial performance metrics are disclosed.

• ·Compliance reports cover activities for year ended December 31, 2025, with attestations dated March 6, 2026 (Ally Bank) and February 26, 2026 (U.S. Bank Trust Company, National Association).
• ·Key exhibits include agreements dated December 14, 2022 (Indenture, Trust Agreement, Pooling Agreement, etc.) and Second Amended and Restated Limited Liability Company Agreement dated November 7, 2018.

27-03-2026

Ally Auto Receivables Trust 2022-2 filed its 10-K annual report on March 27, 2026, covering the year ended December 31, 2025, with financial statements noted as not applicable and a comprehensive list of exhibits including various trust agreements dated October 12, 2022, and compliance assessments from Ally Bank and U.S. Bank Trust Company, National Association. The filing includes standard Part I-IV sections such as Business, Risk Factors, MD&A, and Controls and Procedures, many incorporated by reference. No quantitative financial performance data, period-over-period comparisons, improvements, declines, or flat metrics are provided in the filing excerpt.

• ·Second Amended and Restated Limited Liability Company Agreement dated November 7, 2018.
• ·Compliance reports and attestations for year ended December 31, 2025, including Ally Bank Servicer Compliance Statement and Registered Public Accounting Firm reports dated March 6, 2026, and February 26, 2026.

27-03-2026

JAKKS Pacific, Inc. disclosed the establishment by its Compensation Committee of performance criteria for the 2026 Annual Performance Bonuses of President and CEO Stephen G. Berman and CFO John L. Kimble, based on tiered EBITDA targets starting above $35,587,507 and reaching a maximum above $65,587,507. Berman's base salary is $1,875,000 with a maximum bonus of 300% ($5,625,000), while Kimble's is $632,700 with a maximum of 200% ($1,265,400). Bonuses scale linearly between tiers: 25% for EBITDA >$35.6M to <$45.6M, up to maximum percentages at higher thresholds; adjustments possible for extraordinary items.

• ·EBITDA calculated before bonuses and one-time non-recurring costs for Board-approved initiatives.
• ·Compensation Committee retains discretion to adjust criteria for extraordinary items, strategic transaction fees, or economic conditions.
• ·Event date: March 25, 2026; Filing date: March 27, 2026.

27-03-2026

Ally Auto Receivables Trust 2025-1 filed its 10-K annual report on March 27, 2026, which lists numerous exhibits including key agreements dated October 16, 2025 (e.g., Indenture, Trust Agreement, Servicing Agreement) and compliance reports/assessments for the year ended December 31, 2025. Financial statements and schedules are noted as not applicable. The report covers standard 10-K sections such as Risk Factors, MD&A, Controls and Procedures, and Cybersecurity.

• ·Compliance reports cover year ended December 31, 2025
• ·Registered Public Accounting Firm Attestation Reports dated March 6, 2026 (Ally Bank) and February 26, 2026 (U.S. Bank Trust Company, National Association)
• ·Multiple agreements dated October 16, 2025

27-03-2026

Ally Auto Receivables Trust 2024-1 filed its 10-K annual report on March 27, 2026, listing exhibits including multiple trust-related agreements dated March 13, 2024, and compliance reports for the year ended December 31, 2025. Financial statements and schedules are not applicable. Attestation reports confirm compliance with SEC Regulation AB servicing criteria by Ally Bank (dated March 6, 2026) and U.S. Bank Trust Company, National Association (dated February 26, 2026).

• ·Exhibits include Second Amended and Restated Limited Liability Company Agreement of Ally Auto Assets LLC dated November 7, 2018.
• ·Servicer Compliance Statement of Ally Bank for the year ended December 31, 2025.
• ·10-K covers standard items including Business, Risk Factors, MD&A, Controls and Procedures.

27-03-2026

Ally Auto Receivables Trust 2024-2 filed its 10-K annual report on March 27, 2026, for the year ended December 31, 2025, noting that financial statements and schedules are not applicable. The filing lists numerous exhibits including formation agreements dated September 27, 2024 (e.g., Indenture, Trust Agreement, Servicing Agreement), and compliance reports such as assessments of SEC Regulation AB servicing criteria by Ally Bank and U.S. Bank Trust Company, National Association, for the year ended December 31, 2025. It covers standard 10-K sections like business description, risk factors, and management's discussion and analysis.

• ·Compliance reports dated March 6, 2026 (Ally Bank attestation) and February 26, 2026 (U.S. Bank Trust Company attestation).
• ·Servicer Compliance Statement of Ally Bank for year ended December 31, 2025.

27-03-2026

Ally Auto Receivables Trust 2023-1 filed its 10-K annual report on March 27, 2026, covering the year ended December 31, 2025. The filing lists numerous exhibits including key agreements dated July 19, 2023 (e.g., Indenture, Trust Agreement, Servicing Agreement), compliance assessments from Ally Bank and U.S. Bank Trust Company, National Association, and auditor attestations dated February and March 2026. Financial statements and schedules are noted as not applicable.

• ·Second Amended and Restated Limited Liability Company Agreement of Ally Auto Assets LLC dated November 7, 2018.
• ·Servicer Compliance Statement of Ally Bank for year ended December 31, 2025.
• ·Report on Assessment of Compliance with SEC Regulation AB Servicing Criteria for Ally Bank (year ended December 31, 2025) and U.S. Bank Trust Company, National Association (year ended December 31, 2025).

27-03-2026

Ally Auto Receivables Trust 2022-1 filed its 10-K annual report on March 27, 2026, for the year ended December 31, 2025, listing various exhibits including servicing agreements, trust agreements, and compliance reports from Ally Bank and U.S. Bank Trust Company, National Association. Financial statements and schedules are noted as not applicable. The filing includes attestations on compliance with SEC Regulation AB servicing criteria dated March 6, 2026, and February 26, 2026, with no quantitative financial performance data or period-over-period comparisons provided.

• ·Exhibits include Second Amended and Restated Limited Liability Company Agreement dated November 7, 2018.
• ·Multiple agreements dated May 18, 2022: Indenture, Trust Agreement, Pooling Agreement, Trust Sale Agreement, Custodian Agreement, Administration Agreement, Servicing Agreement, Asset Representations Review Agreement, and Securities Account Control Agreement.
• ·Servicer Compliance Statement of Ally Bank for year ended December 31, 2025.
• ·10-K sections cover Business, Risk Factors, Cybersecurity, MD&A, Controls and Procedures, and others, with many marked as incorporated by reference.

27-03-2026

Scientist Home Future Health Ltd's total assets grew significantly to $644,365 as of December 31, 2025 from $21,248 as of December 31, 2024, driven by increases in cash to $68,888, inventories to $34,006, and new non-current assets including right-of-use assets of $378,944. Revenues rose to $204,055 for the year ended December 31, 2025 (retail trading $197,447 and service $6,608) from $120,775 in the prior stub period, with gross profit up to $81,887; however, operating loss widened sharply to $231,725 from $13,155 due to SG&A expenses surging to $313,612. Stockholders’ equity improved to $113,391 from a $6,020 deficit, supported by $354,000 in share issuances, though accumulated deficit reached $246,705.

• ·Company inception date: July 3, 2024.
• ·Related party transactions: $121,075 cost of retail trading revenue and $19,242 SG&A in 2025; right-of-use assets include $33,435 from related party.
• ·Net loss per share: $(0.01) basic and diluted for 2025.
• ·Weighted average shares: 23,590,425 for 2025.

27-03-2026

Caterpillar Financial Services Corporation commenced its program for the issuance of Medium-Term Notes, Series L on March 27, 2026, under Registration Statement No. 333-294677, with related Prospectus and Prospectus Supplement dated the same day. The filing includes exhibits such as legal opinions from Sidley Austin LLP on the legality and federal tax matters of the notes. No specific issuance amounts or financial impacts were disclosed.

• ·Registration Statement No. 333-294677
• ·Principal executive offices: 2120 West End Avenue, Nashville, Tennessee 37203-0001
• ·Telephone: (615) 341-1000
• ·Commission File Number: 001-11241
• ·IRS Employer Identification Number: 37-1105865
• ·State of Incorporation: Delaware
• ·Trading Symbol: CAT/29 on New York Stock Exchange

27-03-2026

IDEXX Laboratories, Inc. (IDXX) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on March 27, 2026. The filing is procedural in nature, confirming no fee required and classifying it as definitive additional proxy materials under Schedule 14A. No financial metrics, voting items, or substantive updates are provided in the excerpt.

• ·Filing subcategory: Proxy Statement (Additional Materials)
• ·Filed by the Registrant under Section 14(a) of the Securities Exchange Act of 1934

27-03-2026

City Holding Company's DEF 14A Proxy Statement, filed March 27, 2026, solicits votes for the Annual Meeting on April 29, 2026, at 2:00 p.m. at corporate offices in Cross Lanes, WV, including election of four Class III directors for three-year terms and one Class II director for a two-year term, ratification of Crowe LLP as independent auditor for 2026, and an advisory vote on executive compensation. Shareholders of record as of March 16, 2026, are entitled to vote; no financial performance metrics or period-over-period changes are detailed in the provided content.

• ·Record date: March 16, 2026
• ·Meeting location: 25 Gatewater Road, Cross Lanes, WV 25313
• ·XBRL tags indicate pay versus performance disclosures for PEO and Non-PEO NEOs covering 2021-2025, including equity awards, but specific values not provided in excerpt

27-03-2026

Highview Merger Corp., a blank check company (SPAC), filed its 10-K annual report on March 27, 2026, covering the period from inception on April 16, 2025, through December 31, 2025. The company outlines its strategy to acquire businesses with proven or potential significant revenue and earnings growth via organic growth, acquisitions, and operational efficiencies. Risk factors highlighted include potential change in control from substantial Class A ordinary share issuances, debt-related cash flow constraints, and increased vulnerability to economic and regulatory changes.

• ·Financial statements cover period from inception (April 16, 2025) through December 31, 2025
• ·Includes Balance Sheet (Dec 31, 2025), Statement of Operations, Statement of Changes in Shareholders’ Deficit, and Statement of Cash Flows for the inception-to-date period

27-03-2026

Zeo ScientifiX, Inc. (ZEOX) terminated the employment of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer, effective March 23, 2026. The 8-K filing was submitted on March 27, 2026, under Item 5.02. No details on the reasons for termination or any replacement were disclosed.

• ·Registrant details: Nevada incorporation, Commission File Number 000-55008, IRS EIN 47-4180540
• ·Principal executive offices: 3321 College Avenue, Suite 246, Davie, Florida 33314
• ·Telephone: (888) 963-7881

27-03-2026

LCI Industries filed a Definitive Additional Proxy Statement (DEFA14A) for its 2026 Annual Meeting of Stockholders on May 12, 2026, at 9:00 A.M. ET virtually. Shareholders are to vote on electing eight director nominees recommended by the Board, approving executive compensation on an advisory basis, ratifying KPMG LLP as independent auditors for the year ending December 31, 2026, and approving the LCI Industries Amended 2018 Omnibus Incentive Plan. No financial metrics or performance data are provided in the filing.

• ·Vote deadline: May 11, 2026, 11:59 PM ET
• ·Request proxy materials by: April 28, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/LCII2026
• ·Company address: 3501 COUNTY ROAD 6 EAST, ELKHART, IN 46514

27-03-2026

Viewbix Inc.'s 10-K annual report details extensive business risks, including heavy reliance on a single Gix Major Customer for Search Platform revenue, potential disruptions from online platform changes and supply chain issues with Quantum X Labs, and intense competition from Google and Facebook. The independent auditor's report includes an explanatory paragraph on substantial doubt about the company's ability to continue as a going concern, highlighting liquidity and debt concerns. No financial performance improvements are noted, with risks to revenue from data privacy regulations, cyberattacks, and AI implementation challenges also emphasized.

• ·Auditor report (PCAOB ID No. 1197) contains explanatory paragraph on going concern doubt
• ·Significant revenue concentration with one customer (Gix Major Customer)
• ·Risks from global chip shortage, geopolitical tensions (Ukraine, Israel), and supply chain disruptions

27-03-2026

Kezar Life Sciences reported a narrowed net loss of $56.0 million in 2025 versus $83.7 million in 2024, primarily due to sharp declines in research and development expenses ($33.8M from $65.7M, -48.6% YoY) and general and administrative expenses ($18.5M from $23.4M, -20.9% YoY), though restructuring and impairment charges rose to $6.8M from $1.5M. Net cash used in operating activities improved to $51.8M from $74.2M, boosting cash and equivalents to $71.9M from $41.7M. However, total assets fell to $76.6M from $144.7M and stockholders' equity declined to $70.1M from $116.9M amid ongoing cash burn and no revenue.

• ·No collaboration revenue reported in 2025, 2024, or 2023 ($0M each year).
• ·Net loss per common share improved to $(7.66) in 2025 from $(11.49) in 2024.
• ·Stock-based compensation expense declined to $8,963 thousand in 2025 from $13,011 thousand in 2024.

27-03-2026

Alessandro DiNello notified Flagstar Bank on March 25, 2026, of his decision not to stand for re-election at the 2026 Annual Meeting on June 9, 2026, with his term ending at the meeting's conclusion and no disagreements cited. Eli H. Miller was appointed to the Board effective April 1, 2026, to fill the vacancy from Brian Callanan's prior resignation, pursuant to the March 7, 2024 Investment Agreement with Liberty 77 Capital L.P. funds; Mr. Miller will serve on the Risk Assessment Committee and Technology and Operations Committee and receive standard non-employee director pay of $97,500 annual cash retainer and $130,000 annual equity award.

• ·Eli H. Miller's professional background: Senior Managing Director at Liberty Strategic Capital (leadership, fundraising, investments); Managing Director of Government Relations at Blackstone Inc. (April 2019-April 2021); Chief of Staff at U.S. Department of the Treasury (February 2017-April 2019).
• ·No material plan, contract, or arrangement entered or amended in connection with Mr. Miller’s appointment; no Item 404(a) transactions.
• ·Mr. Miller's term expires at the conclusion of the 2026 Annual Meeting.

27-03-2026

International Paper's 2026 Proxy Statement details the virtual annual meeting on May 11, 2026, to elect 11 directors, ratify Deloitte & Touche LLP as independent auditor, and approve NEO compensation on a non-binding basis. In 2025, Packaging Solutions North America achieved 37% YoY adjusted EBITDA growth and 340 basis-point margin expansion amid macro challenges, while returning $977M to shareholders via dividends; however, Packaging Solutions EMEA faced a weak market during early transformation stages. The company completed the sale of its Global Cellulose Fibers business in January 2026 and announced plans to spin off the EMEA business within 12-15 months to create two independent public companies.

• ·Annual meeting record date: March 12, 2026
• ·Sale of Global Cellulose Fibers business completed January 2026
• ·EMEA spin-off announcement: January 2026, expected completion in 12-15 months
• ·New executives joined: Lance Loeffler (April 2025), Melissa Flores (January 2026)
• ·David Robbie joined board February 2025 post-DS Smith acquisition

27-03-2026

Jackson Financial Inc. filed a prospectus supplement on March 27, 2026, enabling the resale of up to 4,715,554 shares of its common stock ($0.01 par value) by a selling securityholder or its permitted transferees. The company will not receive any proceeds from any such sales, and the filing supplements a base prospectus from January 17, 2025, under an existing S-3ASR registration (File No. 333-284340). A legal opinion on the validity of the shares from Skadden, Arps, Slate, Meagher & Flom LLP is included as Exhibit 5.1.

• ·Prospectus supplement filed under Form S-3ASR (File No. 333-284340), effective January 17, 2025.
• ·Annual Report on Form 10-K for year ended December 31, 2025, filed February 24, 2026.

27-03-2026

The 2026 Proxy Statement for Invesco Commercial Real Estate Finance Trust, Inc. seeks stockholder votes to elect six director nominees—R. Scott Dennis (Chair), Julie Arrowsmith, R. David Kelly (Lead Independent Director), J. Ray Nixon, Charlie Rose (CEO), and Paul E. Rowsey—to terms ending at the 2027 Annual Meeting, and to ratify PricewaterhouseCoopers LLP as auditors for 2026. Governance highlights include 4 out of 6 independent directors, a lead independent director, annual board effectiveness reviews, age 75 limit for independent directors, and no overboarding. No financial performance data or period comparisons are provided.

• ·Board unanimously recommends FOR all director nominees; plurality vote required.
• ·Independent directors meet in executive sessions presided by Lead Independent Director.
• ·Insider trading policy prohibits short selling, options, pledging, hedging in company equity.
• ·Annual Meeting for 2026; director terms until 2027 Annual Meeting.
• ·Audit Committee comprised exclusively of independent directors.

27-03-2026

Elevance Health, Inc. (ELV) issued a DEFA14A filing notifying shareholders of the 2026 Annual Meeting on May 13, 2026, at 8:00 a.m. ET in a virtual format only via live audio webcast. Key proposals include the election of directors Gail K. Boudreaux, Robert L. Dixon, Jr., and Deanna D. Strable (Board recommends FOR), advisory vote on named executive officer compensation (FOR), ratification of Ernst & Young LLP as auditors (FOR), and a shareholder proposal for an independent study on prohibiting contributions to partisan 527 groups (AGAINST). Proxy material requests must be made by May 3, 2026, with 401(k) votes due by May 8, 2026.

• ·Virtual meeting access: https://meetnow.global/MRG6YVV (opens 15 minutes prior)
• ·Shareholder login requires control number from proxy notice
• ·Alternative audio access requests by May 11, 2026 via shareholder.services@elevancehealth.com or (800) 985-0999
• ·Proxy voting options: online at www.envisionreports.com/elv, phone 1-866-641-4276, or email investorvote@computershare.com

27-03-2026

Society Pass Incorporated received a Nasdaq Staff Letter on March 26, 2026, notifying that its common stock (SOPA) bid price closed below the $1.00 minimum requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has an initial 180 calendar days until September 22, 2026, to regain compliance by maintaining $1.00 or higher for 10 consecutive business days, with no immediate effect on listing or trading. Failure to comply could lead to delisting, though a potential second 180-day period is available if other listing standards are met; the company plans to monitor and explore options like a reverse stock split.

• ·Securities registered: Common Stock, par value $0.0001 per share, trading symbol SOPA on The Nasdaq Capital Market
• ·Address: 701 S. Carson Street, Suite 200, Carson City, Nevada 89701
• ·Emerging growth company: Yes
• ·Potential second compliance period of 180 calendar days if other Nasdaq Capital Market standards met, excluding bid price

27-03-2026

On March 25, 2026, AB Commercial Real Estate Private Debt Fund, LLC issued a capital call notice to investors for an aggregate offering price of $70,894,009.22 related to its limited liability company units, with the sale expected to close on or around April 1, 2026. The issuance is made pursuant to subscription agreements and is exempt from Securities Act registration under Section 4(a)(2) and Regulation D.

• ·Capital call delivered pursuant to subscription agreements requiring investors to fund up to their capital commitments on an as-needed basis.
• ·Fund's principal executive offices: 66 Hudson Boulevard East, New York, New York 10001.

27-03-2026

O'Reilly Automotive, Inc. (ORLY) filed a DEFA14A Definitive Additional Proxy Materials on March 27, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive financial or operational details are provided in the header.

• ·Filing Type: DEFA14A (Proxy Statement)
• ·Check box: Definitive Additional Materials

27-03-2026

On March 23, 2026, the Compensation Committee of Pulse Biosciences, Inc. awarded Chief Technology Officer Darrin R. Uecker 100,000 restricted stock units (RSUs) of common stock ($0.001 par value) in recognition of his leadership in atrial fibrillation product development efforts. The RSUs vest in full on the third anniversary of the grant date, subject to the terms of the grant agreement and the Company's Amended and Restated 2017 Equity Incentive Plan. No other changes in directors or officers were reported.

• ·Grant made under the Amended and Restated 2017 Equity Incentive Plan
• ·Common stock par value: $0.001 per share
• ·Filing signed by Paul A. LaViolette on March 27, 2026

27-03-2026

CNA Financial Corporation filed a DEFA14A supplement on March 27, 2026, to its definitive proxy statement dated March 20, 2026, for the 2026 Annual Meeting of Stockholders on April 29, 2026. The supplement clarifies the treatment of broker non-votes for proposals 2, 3, and 4, specifying that they will have no effect on the vote (unlike abstentions, which count as votes against), replacing prior language on pages 2 and 39. No changes to the proposals themselves, and no action is needed for prior voters unless they wish to revise their vote.

• ·Original proxy statement filed March 20, 2026
• ·Supplement replaces specific sentence on pages 2 and 39 regarding broker non-votes and abstentions

27-03-2026

CVB Financial Corp (CVBF) held a special shareholder meeting on March 26, 2026, approving the Merger Proposal with Heritage Commerce Corp, pursuant to the Reorganization Agreement, with 103,515,602.13 votes FOR, 57,008 AGAINST, and 50,631 ABSTENTIONS out of 103,623,241.13 shares present (76.31% of 135,792,701 outstanding shares as of February 9, 2026 record date). The merger, requiring a majority of outstanding shares, passed overwhelmingly, allowing Heritage to merge into CVBF and Heritage Bank into Citizens Business Bank. A joint press release was issued announcing the results, with no adjournment needed.

• ·Record date for special meeting: February 9, 2026
• ·No broker non-votes as proposals were non-routine
• ·Adjournment Proposal not acted upon due to sufficient votes for Merger Proposal
• ·Joint press release filed as Exhibit 99.1

27-03-2026

Triple Flag Precious Metals Corp. filed its Form 40-F annual report for the fiscal year ended December 31, 2025, incorporating audited financial statements prepared under IFRS and an annual information form. The company reported 206,531,806 common shares outstanding as of December 31, 2025, with references to a portfolio of mineral streams, royalties, and interests across assets like Kensington, Northparkes, La Colorada, and others. No specific period-over-period financial metrics were detailed in the provided filing content.

• ·Filing date: March 27, 2026
• ·Fiscal year end: December 31, 2025
• ·Principal executive offices: TD Canada Trust Tower, 161 Bay Street, Suite 4535, Toronto, Ontario, Canada M5J 2S1
• ·Agent for service in US: Triple Flag USA Royalties Ltd., c/o Torys LLP, 1114 Avenue of the Americas, 23rd Floor, New York, New York 10036

27-03-2026

Humacyte, Inc. achieved first-year revenue of $2,038 thousand in 2025, up 100% from zero in 2024, with product revenue at $1,389 thousand and contract revenue at $649 thousand. Net loss narrowed 73% to $40,833 thousand from $148,701 thousand, driven by a 22% R&D expense reduction to $69,302 thousand and favorable fair value changes, while total operating expenses declined 4% to $110,175 thousand; however, cash used in operating activities rose 7% to $105,042 thousand, resulting in cash and equivalents dropping to $50,497 thousand from $44,937 thousand (total cash position $50,850 thousand from $95,290 thousand). Stockholders' equity flipped to a positive $3,109 thousand from a $52,669 thousand deficit amid share issuances totaling over 62 million new shares.

• ·Contingent Earnout Liability decreased to $11,492 thousand from $70,961 thousand.
• ·Loss on extinguishment of debt: $22,267 thousand in 2025.
• ·Net cash provided by financing activities: $61,486 thousand in 2025 vs. $114,183 thousand in 2024.
• ·Weighted-average shares outstanding: 158,160,468 in 2025 vs. 118,479,097 in 2024.
• ·Net loss per share: $(0.26) in 2025 vs. $(1.26) in 2024.

27-03-2026

New Mountain Finance Corporation (NMFCZ) has filed a DEF 14A proxy statement for its Annual Meeting of Stockholders on May 12, 2026, at 10:30 a.m. Eastern Time, held virtually at www.virtualshareholdermeeting.com/NMFC2026. The proxy solicits votes for Proposals 1 and 2, appointing John Kline, Adam Weinstein, Laura Holson, Kris Corbett, and Joseph Hartswell as proxies, who will vote FOR the proposals if no direction is given.

• ·Fiscal year reference: 2025-01-01 to 2025-12-31
• ·Proxy voting platform: www.proxyvote.com

27-03-2026

Bank of the James Financial Group reported robust balance sheet expansion with total assets up 6.1% YoY to $1,039M, deposits increasing 6.2% to $937M, net loans growing 3.9% to $661M, and stockholders' equity surging 23.4% to $80M as of December 31, 2025. Net interest margin improved slightly to 4.82% from 4.75%, driven by a 10.1% decline in interest expense on liabilities amid lower funding costs. However, noninterest expenses rose 7.0% YoY to $37.5M, total risk-based capital ratio dipped to 12.54% from 12.84%, and income from SBIC fund declined sharply to $0.5M from $0.9M.

• ·Securities portfolio total amortized cost $236,625K with market value $217,443K at Dec 31, 2025
• ·Tier 1 capital to average total assets stable at 9.05% (2025) vs 9.04% (2024), well above 5% well-capitalized benchmark
• ·Allowance for credit losses coverage of nonperforming loans at 378.50% (2025) vs 429.43% (2024)